Freimut D. Juengling

TO THE EDITOR: The recent editorial in the Journal of Nuclear Medicine highlights the profound risks posed by reductions in federal funding for medical research, emphasizing how such measures threaten not only ongoing innovation but also the infrastructure and talent pipeline essential to the field’s future (1).

Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.

1. Introduction Glioblastoma multiforme (GBM) is the most common type of high-grade primary brain tumor and accounts for approximately 14% of all CNS tumors; it has an annual incidence rate of 3 per 1,00,000 inhabitants (1).